Sleeve gastrectomy, the most common weight-loss operation in the United States, cost between $11,310 and $18,918 less per patient over two years than GLP-1 drugs did. The gap held across every kind of insurance. That is the result of a retrospective study of 90,769 American adults with obesity and type 2 diabetes, published online September 23 in Surgery for Obesity and Related Diseases ↗.
The finding cuts against the usual intuition that surgery is the expensive choice and a prescription is the thrifty one. Over a two-year window, the opposite was true.
What the study counted
The authors pulled all-payer insurance claims from 2017 to 2023 and matched patients one to one so the surgery and drug groups looked alike on age, health, and other measurable traits. They compared total healthcare spending, not just the sticker price of the operation or the drug, for people treated with sleeve gastrectomy, Roux-en-Y gastric bypass, or a GLP-1 receptor agonist. The GLP-1 class is the family of appetite-and-glucose drugs that includes semaglutide ↗, sold as Ozempic and Wegovy, and tirzepatide ↗, sold as Mounjaro and Zepbound.
Against sleeve gastrectomy, the drugs lost on cost in every insurance category. Against gastric bypass, the fuller operation, the two treatments came out roughly even, with one exception: among people with commercial insurance, bypass still ran about $4,973 cheaper.
Who pays changes the math
The sharper finding is in the payor split. Both surgery and drugs cost more under Medicaid and Medicare than under commercial insurance, and the surgery-versus-drug gap was widest on Medicaid, where sleeve gastrectomy saved $18,927 over two years. The number that matters to a patient or an insurer is not "what does this treatment cost" in the abstract. It is "what does it cost given who is paying," and the answer moves by thousands of dollars depending on the card in your wallet.
That points at something structural about GLP-1 economics. Surgery is a front-loaded cost. You pay once, then spending falls. A GLP-1 drug is a recurring cost that keeps running as long as the patient stays on it, and most people who stop regain the weight. A two-year window captures the surgery's bill in full while catching only the opening stretch of a drug that, for many patients, is meant to be permanent.
The authors' own ledger
Three of the five authors work in the health-economics group at Intuitive Surgical, the company that makes the da Vinci robot used in many bariatric operations. The senior author is a bariatric surgeon at Mayo Clinic in Florida. A study concluding that surgery saves money, co-written by employees of a surgical-device maker, is worth reading with that on the table. The claims data and the matching are standard practice, but a propensity-matched cohort is not a randomized trial. It balances the traits you can measure and stays blind to the ones you cannot, and the people who choose surgery differ from the people who choose a drug in ways no billing database fully captures.
This is the second time our coverage has landed on surgery being cheaper. An Israeli cohort followed for up to 12.5 years also found GLP-1 drugs cost more than weight-loss surgery ↗, even after setting the price of the drugs and the operations aside. The two studies answer slightly different questions. The Israeli one stripped out the treatment prices and still found surgery won on downstream costs over a decade. This one keeps the treatment prices in, finds surgery wins within two years, and then shows the size of the win depends on who holds the bill.